cetylpyridinium chloride anhydrous has been researched along with Autoimmune Thrombocytopenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amadori, S; Newland, AC; Osborn, J; Provan, D; Stasi, R | 1 |
| Breunis, WB; Bruin, M; de Boer, M; de Haas, M; Geissler, J; Koene, HR; Kuijpers, TW; Peters, M; Roos, D; van Mirre, E | 1 |
2 other study(ies) available for cetylpyridinium chloride anhydrous and Autoimmune Thrombocytopenia
| Article | Year |
|---|---|
Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Health; Humans; Incidence; Male; Middle Aged; Platelet Count; Prognosis; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Time Factors | 2006 |
Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura.
Topics: Animals; Antibodies; Antigens, CD; Cells, Cultured; Genetic Predisposition to Disease; Genotype; Haplotypes; Health; Humans; Killer Cells, Natural; Lymphocyte Activation; Mice; Multigene Family; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Purpura, Thrombocytopenic, Idiopathic; Receptors, IgG | 2008 |